Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective

被引：2
|
作者：
Xu, Xu Steven [1 ]
Yan, Xiaoyu [1 ]
Puchalski, Thomas [2 ]
Lonial, Sagar [3 ]
Lokhorst, Henk M. [4 ]
Voorhees, Peter M. [5 ]
Liu, Kevin [1 ]
Khan, Imran [1 ]
Jansson, Richard [2 ]
Ahmadi, Tahamtan [2 ]
Ruixo, Juan Jose Perez [6 ]
Zhou, Honghui [2 ]
Clemens, Pamela L. [2 ]
机构：
[1] Janssen Res & Dev LLC, Raritan, NJ USA
[2] Janssen Res & Dev LLC, Spring House, PA USA
[3] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA
[4] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[5] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol Oncol, Chapel Hill, NC 27599 USA
[6] Janssen Res & Dev, Beerse, Belgium
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.4254.4254
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 41 条
  • [1] Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
    Oostvogels, Rimke
    Jak, Margot
    Raymakers, Reinier
    Mous, Rogier
    Minnema, Monique C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (01) : 60 - 67
  • [2] EFFICACY OF RETREATMENT WITH IMMUNOMODULATORY DRUGS AND PROTEASOME INHIBITORS FOLLOWING DARATUMUMAB TREATMENT IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS
    Oostvogels, R.
    Jak, M.
    Minnema, M. C.
    HAEMATOLOGICA, 2018, 103 : 33 - 33
  • [3] A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs)
    Gasparetto, Cristina J.
    Lentzsch, Suzanne
    Schiller, Gary J.
    Bensinger, William
    Bahlis, Nizar J.
    Sutherland, Heather J.
    White, Darrell J.
    Sebag, Michael
    Kotb, Rami
    Venner, Christopher P.
    LeBlanc, Richard
    Chen, Christine I.
    Del Col, Aldo
    Kauffman, Michael G.
    Shacham, Sharon
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    Lipe, Brea C.
    BLOOD, 2017, 130
  • [4] Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment
    Pamela L. Clemens
    Xiaoyu Yan
    Henk M. Lokhorst
    Sagar Lonial
    Nedjad Losic
    Imran Khan
    Richard Jansson
    Tahamtan Ahmadi
    Kristen Lantz
    Honghui Zhou
    Thomas Puchalski
    Xu Steven Xu
    Clinical Pharmacokinetics, 2017, 56 : 915 - 924
  • [5] Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment
    Clemens, Pamela L.
    Yan, Xiaoyu
    Lokhorst, Henk M.
    Lonial, Sagar
    Losic, Nedjad
    Khan, Imran
    Jansson, Richard
    Ahmadi, Tahamtan
    Lantz, Kristen
    Zhou, Honghui
    Puchalski, Thomas
    Xu, Xu Steven
    CLINICAL PHARMACOKINETICS, 2017, 56 (08) : 915 - 924
  • [6] Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis
    Yan, Xiaoyu
    Clemens, Pamela L.
    Puchalski, Thomas
    Lonial, Sagar
    Lokhorst, Henk M.
    Orlowski, Robert Z.
    Losic, Nedjad
    Khan, Imran
    Jansson, Richard
    Ahmadi, Tahamtan
    Lantz, Kristen
    Ruixo, Juan Jose Perez
    Zhou, Honghui
    Xi, Xu Steven
    BLOOD, 2015, 126 (23)
  • [7] Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
    Xu, X. S.
    Yan, X.
    Puchalski, T.
    Lonial, S.
    Lokhorst, H. M.
    Voorhees, P. M.
    Plesner, T.
    Liu, K.
    Khan, I.
    Jansson, R.
    Ahmadi, T.
    Ruixo, J. J. Perez
    Zhou, H.
    Clemens, P. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (06) : 721 - 724
  • [8] Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
    Yalniz, Fevzi Firat
    Akkoc, Nihan
    Salihoglu, Ayse
    Ar, M. Cem
    Ongoren, Seniz
    Eskazan, A. Emre
    Soysal, Teoman
    Aydin, Yildiz
    TURKISH JOURNAL OF HEMATOLOGY, 2017, 34 (03) : 233 - 238
  • [9] Patient characteristics and treatment patterns in relapsed/refractory multiple myeloma patients after exposure to a proteasome inhibitor, an immunomodulatory agent and daratumumab.
    Mehra, Maneesha
    Vogel, Martin
    Valluri, Satish
    Nair, Sandhya
    Schecter, Jordan
    Jagannath, Sundar
    Weisel, Katja
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Pomalidomide, Cyclophosphamide and Dexamethasone (PCD) is an Effective Salvage Regimen for Multiple Myeloma (MM) Patients Relapsed and/or Refractory to Daratumumab
    Brioli, Annamaria
    Mancuso, Katia
    Ernst, Thomas
    Hilgendorf, Inken
    Zamagni, Elena
    Heidel, Florian
    Stauch, Thomas
    Hochhaus, Andreas
    von Lilienfeld-Toal, Marie
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 129 - 130
12345